U.S. FDA Clears Takeda Uloric For Gout Indication
This article was originally published in PharmAsia News
Executive Summary
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years
You may also be interested in...
Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound
Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan
Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound
Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan
Takeda Readying To Launch PPI Kapidex Within A Month
TOKYO - Takeda expects to launch within a month its Kapidex (dexlansoprazole) delayed- release capsules for the treatment of gastroesophageal reflux disease, the same proton pump inhibitor class of drugs as its Prevacid, which is scheduled to lose patent protection this year, according to the company's third-quarter earnings call Feb. 3